Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Affy Sues Illumina in genome-analysis and array technologies

    Affy recently(Oct 26th, 2007) filed additional patent-infringement lawsuit against Illumina.

    See detail news:


    Due to significance of the decision, we will discuss about patent claims in near future.

  • #2
    Great topic to start off this forum, thanks B.

    This Forbes article has a bit more info, particularly the patent filings that Affy is claiming are infringed upon:

    In the new suits Affymetrix accuses Illumina of infringing US Patents No. 5,902,723, No. 6,403,320, No. 6,420,169, No. 6,576,424, and No. 7,056,666; and in the UK and Germany under European Patents No. 0834575, No. 0853679, and No. 0799897.
    Google patent links here:
    • 5,902,723: Analysis of surface immobilized polymers utilizing microfluorescence detection
    • 6,403,320: Support bound probes and methods of analysis using the same
    • 6,420,169: Apparatus for forming polynucleotides or polypeptides
    • 6,576,424: Arrays and methods for detecting nucleic acids
    • 7,056,666: Analysis of surface immobilized polymers utilizing microfluorescence detection


    There is a fair amount of information on Affy's investor webpage

    Comment


    • #3
      Just to complete this discussion, it seems that the dispute was settled.

      Press Release on Affymetrix's web page

      and see also the thread started by ECO:
      The more you know, the more you know you don't know. —Aristotle

      Comment


      • #4
        I am very interested in the impact of this patent dispute on users. Any comments will be appreciated!

        Comment


        • #5
          I haven't felt any impact. What are some ways there may be an impact?
          Providing nextRAD genotyping and PacBio sequencing services. http://snpsaurus.com

          Comment


          • #6
            Maybe the effect was that some potential user/buyers were discouraged from buying Illumina because of the pending lawsuit during the litigation.

            For example, Affy was seeking an injunction against any sale of Illumina products. So if the injunction was approved by the court, the choice of Illumina may have seemed risky to buyers/users during the litigation.

            Comment


            • #7
              We bought a GAII in early 2008, so were considering a purchase during this timeframe. I don't think it weighed heavily in the discussion for us. It seems that these large companies sue each other all the time, but nearly always find a way to continue doing business after some payment is made.
              Providing nextRAD genotyping and PacBio sequencing services. http://snpsaurus.com

              Comment


              • #8
                Thanks SNPsaurus for comment. So the many patent lawsuit are the games among manufacturers, and users in this market do not get affected. Very helpful!

                Comment

                Latest Articles

                Collapse

                • seqadmin
                  The Impact of AI in Genomic Medicine
                  by seqadmin



                  Artificial intelligence (AI) has evolved from a futuristic vision to a mainstream technology, highlighted by the introduction of tools like OpenAI's ChatGPT and Google's Gemini. In recent years, AI has become increasingly integrated into the field of genomics. This integration has enabled new scientific discoveries while simultaneously raising important ethical questions1. Interviews with two researchers at the center of this intersection provide insightful perspectives into...
                  02-26-2024, 02:07 PM
                • seqadmin
                  Multiomics Techniques Advancing Disease Research
                  by seqadmin


                  New and advanced multiomics tools and technologies have opened new avenues of research and markedly enhanced various disciplines such as disease research and precision medicine1. The practice of merging diverse data from various ‘omes increasingly provides a more holistic understanding of biological systems. As Maddison Masaeli, Co-Founder and CEO at Deepcell, aptly noted, “You can't explain biology in its complex form with one modality.”

                  A major leap in the field has
                  ...
                  02-08-2024, 06:33 AM

                ad_right_rmr

                Collapse

                News

                Collapse

                Topics Statistics Last Post
                Started by seqadmin, 02-28-2024, 06:12 AM
                0 responses
                30 views
                0 likes
                Last Post seqadmin  
                Started by seqadmin, 02-23-2024, 04:11 PM
                0 responses
                74 views
                0 likes
                Last Post seqadmin  
                Started by seqadmin, 02-21-2024, 08:52 AM
                0 responses
                86 views
                0 likes
                Last Post seqadmin  
                Started by seqadmin, 02-20-2024, 08:57 AM
                0 responses
                71 views
                0 likes
                Last Post seqadmin  
                Working...
                X